Amgen's high-profile cancer med Lumakras set for rollout in England thanks to NHS access deal

Only months after Amgen kicked off its U.S. launch for lung cancer drug Lumakras, the med is set to make its debut in England.

Thanks to a deal between the drugmaker and NHS England, about 600 patients in the country per year will be able to access the novel therapy. Patients in England will be the first in Europe to receive the drug, known there as Lumakras.